The immunotherapy drug first earned FDA approval to treat urothelial carcinoma — the most common type of bladder cancer — in May 2016. The FDA also approved the drug as a second-line treatment for metastatic non-small cell lung cancer in October 2016.
Tecentriq can now be used to treat patients with advanced bladder cancer who are not eligible for standard chemotherapy, according to the report.
More articles on supply chain:
Medtronic sells majority of medical supplies unit to Cardinal for $6.1B
Bristol-Myers will license drugs to Biogen, Roche for $470M
FDA rejects Eli Lilly’s arthritis drug
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
